Negotiated drugs how to reimbursement process

According to the normal health insurance reimbursement process can be. If you want to health insurance off-site direct reimbursement settlement, you need to go through these processes first: you have to first register for the record, select the point of care and then hold the card for medical treatment. Reimbursement requires a copy of the original ID card, a copy of the original Nonghe medical card. As well as the hospitalization certificate discharge certificate, hospitalization charges, discharge charges and diagnostic certificates and copies of medical records. If the off-site reimbursement on the ID card and medical card and discharge documents on the line, off-site reimbursement has not been carried out on the need for the above that cut back to the local social security bureau management of the medical hall, or health insurance bureau of the medical management hall on the line; if it is a local reimbursement, the hospital with an ID card and medical insurance card in the hospitalization procedures, according to the provisions of the hospital and the requirements of the prepaid deposit. Ensure that part of the expenses in the hospital into the medical insurance reimbursement. After the admission procedures are completed, the nurse will give you a sheet, they get the hospital's new rural cooperative window to register on the line, and so on the time of discharge with the doctor to give you the relevant procedures directly to the new rural cooperative window for discharge settlement.

Legal basis:

National Essential Drugs Catalogue (NEDC) IV. Negotiated medicines within the agreement period (a) Western medicines B 99 Zebutinib Oral Normal-Release Dosage Forms Limitations: 1. Adults who have received at least one type of treatment in the past for lymphoma cell cushingtonioma (MCL) patients. 2. Adults who have received at least one type of treatment in the past for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) patients. 3. Adults who have received at least one type of treatment for chronic lymphocytic lymphocytic lymphoma (MCL) patients. 4. Adult chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) patients who have received at least one prior therapy. March 1, 2021 through December 31, 2022